Basel Medical Group Ltd Ordinary Shares

Basel Medical Group Ltd Ordinary Shares

BMGL
Basel Medical Group Ltd Ordinary SharesUS flagNASDAQ Global Market
5.87
USD
+0.48
- -
9.19MMarket Cap
Basel Medical Group Ltd Ordinary Shares
BMGL
(NASDAQ Global Market)

Recent

price

5.87

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
FRC
0.66
0.53
0.54
- -
Revenue per Share
0.12
0.1
0.11
- -
Basic EPS, GAAP
0.17
0.14
0.14
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
0.23
0.3
1.73
- -
Book Value per Share
0.23
0.3
0.41
- -
Tangible Book Value per Share
16
18
18
- -
Basic Weighted Avg Shares
11
10
10
11
Sales/Revenue/Turnover
23.21
21.38
21.84
-19.22
Operating Margin (%)
1
1
1
1
Depreciation Expense
2
2
2
-11
Net Income, GAAP
17.12
16.34
13.8
- -
Effective Tax Rate (%)
18.56
18.38
20.62
-93.96
Profit Margin (%)
8
8
9
3
Working Capital
6
3
2
3
LT Debt
4
5
8
5
Total Equity
- -
12.9
15.11
- -
Return on Invested Capital (%)
- -
14.93
9.08
- -
Return on Capital (%)
- -
38.79
11.05
-34.1
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-28.08%
Free Cash Flow
- -
- -
-244.62%
Net Income, GAAP
- -
- -
-613.11%
Sales/Revenue/Turnover
- -
- -
12.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
10
2024
- -
- -
- -
- -
10
2025
- -
- -
- -
- -
11

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.1
2024
- -
- -
- -
- -
0.11
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Basel Medical Group Ltd (Nasdaq: BMGL), a British Virgin Islands holding company founded in 2023 and headquartered at Kingston Chambers in Road Town, Tortola, operates through Singapore-based subsidiaries to provide specialized healthcare services in Singapore and Southeast Asia. The company offers general and subspecialized orthopedic services including knee and hip replacements, sports medicine and surgery, spine surgery, foot and ankle surgery, minimally invasive orthopedic procedures, and trauma care; neurosurgical treatments for complex neurological conditions; physiotherapy and rehabilitative therapy; family clinic services and health screenings; as well as consultation, medical diagnosis, magnetic resonance imaging, x-ray, lump removal, general surgery, and non-surgical treatments. It builds an integrated healthcare ecosystem across four core pillars of medical practices with expanding specialist portfolios, medical supplies and equipment, cutting-edge medical technologies, and pharmaceuticals through an extensive regional pharmacy network, primarily targeting corporate clients in construction, marine, oil and gas industries alongside individual patients driven by aging populations, rising incomes, and sports participation. Recent developments include its February 2025 Nasdaq initial public offering at $4.00 per share; completion of the acquisition of Bethesda Medical in April 2025 to strengthen its healthcare ecosystem in Singapore and Southeast Asia; a May 2025 announcement of exclusive negotiations with institutional investors and high-net-worth individuals for a $1 billion Bitcoin treasury acquisition to bolster its balance sheet, enhance M&A flexibility, and fuel Asian expansion (subsequently placed on hold in July 2025); award of a S$375 million five-year contract in May 2025 to a subsidiary by Pancare Technology International for healthcare product supply in Asia-Pacific with AI-integrated supply chain enhancements; appointment of a Chief Commercial Officer in August 2025; and resignation of its Chief Partnership Officer in August 2025. Basel Medical Group Ltd maintains two clinics at 6 Napier Road in Gleneagles Medical Centre, Singapore, employs 32 staff, and positions itself to capitalize on private healthcare growth in the region.

Company News

APIChatGPT
  • BMGL Regains Compliance With Nasdaq Minimum Bid Price Requirement

  • BMGL Regains Compliance With Nasdaq Minimum Bid Price Requirement

  • QingSong Health Corp (2661.HK) and Basel Medical Sign Strategic Cooperation Memorandum to Explore AI Healthcare Services in Southeast Asia

  • BMGL to Effect Reverse Share Split on June 22, 2026

  • BMGL to Effect Reverse Share Split on June 22, 2026

  • BMGL Investors Have Opportunity to Join Basel Medical Group Ltd Fraud Investigation with the Schall Law Firm

  • Rosen Law Firm Encourages Basel Medical Group Ltd. Investors to Inquire About Securities Class Action Investigation – BMGL

  • Rosen Law Firm Encourages Basel Medical Group Ltd. Investors to Inquire About Securities Class Action Investigation – BMGL

  • Compliance With Nasdaq Periodic Filing Requirement

  • Receipt of Delinquency Notification from Nasdaq

  • Basel Medical Group (NASDAQ:BMGL) Trading 1.5% Higher – Time to Buy?

  • Receipt of Delinquency Notification from Nasdaq

  • Basel Medical Group Putting On Hold On The Acquisition of BTC Digital Asset

  • Basel Medical Obtains Waiver of Lock-Up for Potential Strategic Fund Raising

  • Basel Medical Group Ltd Reaffirms Strong Financial Position Amid Market Volatility

  • Basel Medical Group Ltd Enters into US$ 1.0 Billion Bitcoin (BTC) Purchase Agreement

  • Basel Medical Group Subsidiary Awarded S$375 Million Contract to Supply Healthcare Products; Group to Enhance AI-Powered Healthcare Supply Chain Capabilities

  • Basel Medical Group Ltd Kicks Off US$ 1.0 Billion Bitcoin (BTC) Acquisition Strategy Move

  • Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia

  • Basel Medical Group Signs Agreement to Acquire Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia